Solid Tumors | CHOP Research Institute

Lurbinectedin in Ewing Sarcoma

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Nicholas F. Evageliou, MD

Dr. Evageliou is an attending physician in the Division of Oncology. His research interest is in renal tumors, neuroblastoma, and solid tumors. He is a member of the Renal Tumors Committee of the Children's Oncology Group, where he helps create clinical trials for Wilms tumors.

E-mail:

evageliou [at] chop.edu

BA3011 for advanced solid tumors

ON-TRK

The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.

Lutathera in Somatostatin Neuroendocrine Tumors

This study involves taking a study drug called Lutathera.

Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma

The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma.

Copanlisib in Solid Tumors or Lymphoma

The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.

Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes).

Selpercatinib in Solid or CNS tumors with RET-Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called Selpercatinib in children whose cancers have a specific genetic change (RET-fusion or RET-mutation).

Abemaciclib For Solid Tumors

The purpose of this study is to determine the highest safe dose of abemaciclib in patients with relapsed or treatment refractory solid tumors given in combination with the chemotherapy drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide (Part B).